Welcome to our dedicated page for Inogen news (Ticker: INGN), a resource for investors and traders seeking the latest updates and insights on Inogen stock.
Inogen Inc. (INGN) is a pioneering medical technology company committed to enhancing the quality of life for supplemental oxygen users. Founded in 2001, Inogen emerged from a personal story of necessity and innovation. The company's mission began when Mae, the grandmother of one of the founders, was prescribed oxygen therapy, highlighting the need for more user-friendly and portable oxygen solutions. You can learn more about Mae's story here.
Inogen aims to revolutionize oxygen therapy technology, striving to keep pace with the active lifestyles of patients who rely on oxygen to lead fulfilling lives. The company estimates that over 2.5 million patients in the United States and more than 4.5 million patients worldwide use oxygen therapy.
The company's flagship product, the Inogen One system, is a compact, lightweight, and travel-approved portable oxygen concentrator designed to liberate patients from the constraints of heavy tanks, frequent refills, and stationary systems. This innovation provides patients with the freedom and independence to live their lives by moments, not by the minutes left in an oxygen tank.
Inogen's products and services are sold through various channels, including home medical equipment providers, distributors, large gas companies, and home oxygen providers. The company also rents its products directly to patients, generating the majority of its revenue within the United States.
Inogen's commitment to continuous improvement is evident in its ongoing projects and recent achievements. The company constantly works toward refining its product offerings and expanding its reach to benefit more patients globally.
Inogen, a medical technology company, has appointed Elizabeth (Beth) Mora to its Board of Directors, effective May 24, 2021. Mora, a seasoned executive with extensive financial expertise, fills the vacancy left by R. Scott Greer, who resigned from the board. She will also serve on the Audit Committee. CEO Nabil Shabshab expressed confidence in Mora's ability to enhance strategic initiatives aimed at increasing patient access to oxygen therapy products. The board transition aims to strengthen governance and support Inogen's growth objectives, scheduled for review at the 2024 annual meeting.
Inogen, Inc. (NASDAQ: INGN), a leader in respiratory health technologies, will present at the 41st Annual William Blair Virtual Growth Stock Conference on June 3rd, 2021, at 4:00 p.m. CDT. CEO Nabil Shabshab and CFO Alison Bauerlein will lead the presentation, which can be accessed via the company's Investor Relations page. This presentation highlights Inogen's commitment to innovation in portable oxygen concentrators, enhancing care options for patients with chronic respiratory conditions.
Inogen, Inc. (NASDAQ: INGN) reported Q1 2021 revenue of $86.9 million, a 1.8% decline from Q1 2020, largely due to COVID-19 impacts. Domestic business-to-business revenue rose 11.6% to $30.7 million, while rental revenue surged 84.2% to $9.9 million. As of March 31, 2021, cash and equivalents totaled $233.2 million, with no debt. Operating loss was $2.1 million, and net loss was $0.7 million. The company refrained from providing full-year guidance for 2021 due to pandemic uncertainties, while anticipating increased operational expenses as it invests in growth initiatives.
Inogen, a medical technology company focused on respiratory products, will announce its first quarter 2021 financial results on May 4, 2021, after market close. A conference call will follow at 1:30 PM PT/4:30 PM ET, with a replay available until May 18, 2021. Investors can listen live via phone or through Inogen's Investor Relations website. The company specializes in portable oxygen concentrators for patients with chronic respiratory conditions.
Inogen, Inc. (NASDAQ: INGN) announced the appointment of George Parr as Executive Vice President and Chief Commercial Officer, effective April 12, 2021. This follows the planned departure of Byron Myers and Arron Retterer, effective June 4, 2021. Inogen expects first-quarter 2021 revenue to range from $84.0 million to $87.0 million, based on preliminary estimates. Parr brings over 25 years of experience in the medical technology sector, which the company hopes will enhance growth and patient access to its products. The leadership changes aim to strengthen Inogen’s market position.
Inogen, a medical technology company known for innovative respiratory products, will present at the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021. President and CEO Nabil Shabshab and CFO Alison Bauerlein will host the presentation at 10:15 a.m. ET. Interested parties can access the webcast on Inogen's Investor Relations website, with a replay available for 90 days following the event. Inogen specializes in portable oxygen concentrators designed for long-term supplemental oxygen therapy in homecare settings.
Inogen, Inc. (NASDAQ: INGN), a medical technology company, announced its participation in the KeyBanc Life Sciences & MedTech Investor Forum. The presentation is scheduled for March 23, 2021, at 3:30 p.m. ET, featuring President and CEO Nabil Shabshab, and CFO Alison Bauerlein. Interested individuals can access the webcast on Inogen's Investor Relations page. The company emphasizes transparency by utilizing its website to disclose non-public material information in compliance with Regulation FD. Inogen develops innovative portable oxygen concentrators for patients with chronic respiratory conditions.
Inogen, a medical technology company, reported Q4 2020 revenue of $74 million, down 6.3% year-over-year, primarily impacted by COVID-19. Domestic B2B sales rose 17.9% to $24.2 million, while rental revenue surged 71.7% to $9.4 million. The company incurred a net loss of $5.1 million and had cash reserves of $231.2 million with no debt. For 2021, Inogen refrained from providing financial guidance due to market uncertainties but anticipates improvements in domestic sales and rental revenue despite expected declines in international and direct-to-consumer sales.
Inogen, Inc. (NASDAQ: INGN) announced the appointment of Kristen Miranda to its Board of Directors, effective March 1, 2021, filling the vacancy left by Scott Beardsley’s resignation. Miranda brings extensive healthcare experience, having served as Aetna’s West Region President since 2017. Her addition aims to enhance payor acceptance of Inogen’s products. CEO Nabil Shabshab emphasized her healthcare background as a key asset for expanding patient access and enhancing shareholder value. The company continues to focus on innovative respiratory solutions for homecare settings.
Inogen, Inc. (NASDAQ: INGN) announced its participation in the 10th Annual SVB Leerink Healthcare Conference, scheduled for February 25, 2021. CEO Nabil Shabshab and CFO Alison Bauerlein will present at 2:20 p.m. ET. The presentation can be accessed via the Investor Relations page on Inogen's website, with a replay available for 90 days post-event. Inogen focuses on developing innovative respiratory products, particularly portable oxygen concentrators for patients with chronic respiratory conditions.
FAQ
What is the current stock price of Inogen (INGN)?
What is the market cap of Inogen (INGN)?
What does Inogen Inc. do?
What is Inogen's flagship product?
How does Inogen sell its products?
Where does Inogen generate most of its revenue?
How many patients use oxygen therapy according to Inogen?
What makes Inogen's products stand out?
What is the mission of Inogen Inc.?
Who inspired the founding of Inogen?
Where can I learn more about Inogen's history?
What is Inogen Inc.'s stock symbol?
